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Impact of humoral alloreactivity early after transplantation on and type, have a strong impact on the long-term survival
the long-term survival of renal allografts. of renal allografts because they may be related to the
Background. The contribution of humoral alloreactivity to development of chronic rejection [1–3]. Rejections with-the rejection of renal allografts is not well defined because
out residual impairment of transplant function are innoc-humoral antigraft reactions are not easily detectable in trans-
uous, whereas rejections followed by organ dysfunctionplant biopsies, and serial measurements of circulating allo-
antibodies in the post-transplantation period are not routinely convey an unfavorable long-term prognosis [4, 5]. Like-
performed. We have developed diagnostic techniques that im- wise, acute vascular, in contrast to interstitial, rejections
prove the assessment of humoral alloreactivity in vivo and in predicted both early and late graft loss [6]. Since anti-vitro.
T-cell–directed immunosuppressive therapy in recentMethods. Humoral alloreactivity in transplant biopsies de-
years has failed to improve the cumulative long-termrived from 218 single kidney grafts was detected by assessing
the deposition of complement fragment C4d in interstitial capil- survival of renal allografts, not only T-cell–mediated re-
laries. Circulating alloantibodies were determined in corre- actions, but other, less well-defined pathogenetic mecha-
sponding serum samples by flow cytometry using lymphoblas-
nisms may be operative in severe transplant rejections.toid cell lines of donor DR-type as target cells and by a
Although the association of antidonor antibody andconventional microcytotoxicity test. The impact of capillary
C4d and other selected variables on renal graft survival was subsequent graft loss has been described for decades [7],
calculated by univariate and multivariate analysis. the precise role of humoral alloreactivity has remained
Results. Capillary C4d, present in 46% of biopsies from first elusive because humoral immune reactants are usually
grafts and 72% of regrafts, is related to circulating alloantibod-
not detectable in graft biopsies, and serial measurementsies. Grafts with capillary C4d have a markedly shorter survival
of circulating alloantibodies in the post-transplantationthan grafts without capillary C4d (50% graft survival, 4 vs. 8
years, P 5 0.0001). Among several risk factors, capillary C4d is period are not routinely performed. We have developed
the strongest predictor of subsequent graft loss in a multivariate diagnostic techniques that improve the detection of hu-
analysis (relative risk, 2.1, 95% CI, 1.4 to 3.1). Humoral allore- moral antigraft reactions in vivo and in vitro.activity detectable within six months after transplantation has
Our analysis takes into account the following: (1) En-a much stronger impact on graft survival than alloreactivity
dothelial cells within organ grafts form the primary tar-detected beyond this period.
Conclusions. Humoral alloreactivity, manifested by the cap- gets for immunologic attacks, but will very rapidly remove
illary deposition of complement C4d in about 50% of biopsied deposited antibodies and most complement components
renal grafts, exerts a strong impact on graft survival when it from their surface. Conventional immunohistochemistryoperates within six months after transplantation.
fails to detect transiently bound humoral immune re-
actants in graft capillaries. Transient deposition of anti-
bodies can be visualized, however, by the assessment ofClinical and experimental observations suggest that
complement fragment C4d, a stable remainder of classicacute transplant rejections, depending on their severity
complement activation within capillaries in vivo [8].
(2) Human capillary endothelial cells, in contrast to
rodents, express both human lymphocyte antigen (HLA)Key words: graft rejection, complement C4d, antibody, end-stage renal
disease, chronic rejection, organ dysfunction. class I and class II molecules with high density even
under normal physiological conditions [8, 9]. Therefore,Received for publication August 31, 1999
the analysis of circulating alloantibodies in the clinicaland in revised form June 12, 2000
Accepted for publication July 18, 2000 situation has to include class II-reactive antibodies. Con-
ventional microcytotoxicity assays have low sensitivityÓ 2001 by the International Society of Nephrology
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Table 1. Characteristics of renal transplant recipients, donors, Transplant biopsies
and renal grafts included in this study
A total of 310 biopsies from 218 renal transplants had
Variables Number of casesa been collected since 1988. Grafts were biopsied because
Recipient age #45/.45 years 122/95 (1) of functional impairment or development of persistent
Recipient sex female/male 83/135
proteinuria after exclusion of mechanical factors by clini-Preformed panel-reactive antibodies #5/.5% 153/56 (9)
Number of transplantations 1/.1 151/67 cal and radiological diagnostic techniques. Biopsy sam-
Donor age #45/.45 years 128/79 (11) ples were divided and processed for the preparation of
Donor sex female/male 78/131 (9)
cryostat slides and paraffin-embedded sections in paral-Mismatches HLA-A and -B 0/$1 35/177 (6)
Mismatches HLA-DR 0/$1 135/77 (6) lel. Cryostat slides and paraffin-embedded sections were
Cold ischemia time #20/.20 hours 33/175 (10) evaluated independently in the Institute of Immunology
Acute tubular necrosis no/yes 79/121 (18)
and in the Institute of Pathology, respectively. Diagnos-Acute rejection no/yes 81/137
CMV infections no/yes 189/25 (4) tic classification of graft biopsies followed standard histo-
Graft losses no/yes 89/129 pathological criteria [12], and the Banff working classifi-
a Missing values are in parentheses. cation was applied after 1994 [13].
Assessment of capillary deposition of complement
C4d in graft biopsies
and are likely to miss class II-reactive antibodies when
Cryostat sections prepared from postoperative graft
peripheral lymphocytes are used as targets. Sensitive cy- biopsies were used in indirect immunoperoxidase stain-
tofluorimetric methods and target cells that also display ing as described in detail previously [11]. In brief, cryo-
class II antigens, such as Epstein-Barr virus (EBV)-trans- stat sections were fixed in ice-cold acetone and washed
formed lymphoblastoid cell lines (LCLs), can greatly with phosphate-buffered saline (PBS; pH 7.4). The sec-
improve the detection of circulating alloantibodies in tions were incubated with a dilution of the indicated first
vitro [10]. antibody and, after washing, with the peroxidase-labeled
Our study reports that humoral antigraft responses secondary antibody. Finally, specimens were stained
were detectable in about half of renal transplant recipi- with 3-amino-9-ethyl-carbazole (Sigma, Deisenhofen,
ents who underwent biopsy. We analyzed the survival Germany), dimethylsulfoxide, and H2O2 and were coun-
of grafts with and without capillary deposition of comple- terstained with hemalaun before they were embedded in
ment C4d and compared the impact of early and late glycerol gelatin (all from Merck, Darmstadt, Germany).
alloimmune reactions.
Detection of circulating alloantibodies in
serum samples
METHODS Corresponding serum samples at the time of biopsy
Recipients of renal grafts were collected from 48 graft recipients and were stored at
2208C until further analysis. Circulating alloantibodiesThis study includes 218 recipients of cadaveric renal
were measured by two-color flow cytometry and by agrafts transplanted between 1982 and 1997 at the division
conventional microcytotoxicity panel test.of transplant surgery, Klinikum Großhadern, Munich,
The two-color flow cytometric analysis was performedGermany. A subgroup of patients with early graft dys-
with EBV-transformed LCLs (Table 2) homozygous forfunction was included in a previous study [11]. All recipi-
HLA-DR specificities of donor type [14, 15], as describedents had a negative cross-match with donor lymphocytes
in detail previously [10].The allele assignment of theprior to transplantation. Further details concerning do-
former HLA-DR specificities 2, 3, 5, and 6 has been
nor and recipient risk factors are given in Table 1.
specified according to the recent nomenclature. There-
fore, the serum reactivity against all of the LCLs listed inImmunosuppressive therapy
Table 2 carrying these previous equivalents of HLA-DR
Immunosuppressive therapy in recipients was started was tested. In brief, 9 3 104 LCLs were incubated with
either with a triple drug regimen (cyclosporine, steroids, patient serum and, after washing, with fresh human se-
azathioprine) or, in patients with immunologic risk fac- rum as the complement source. Subsequently, cells were
tors (presence of panel-reactive antibodies and/or pre- incubated with phycoerythrin (PE)-labeled anti-human
viously rejected grafts), a quadruple regimen, including IgG, and fluorescein isothiocyanate (FITC)-conjugated
polyvalent or monoclonal antilymphocyte antibodies. anti-human complement fragment C4c. A minimum of
Rejections were treated with high-dose steroids for three 8000 cells per sample were then analyzed in a FACScan
days and, if unresponsive, with antilymphocyte antibod- (Becton Dickinson, Mountain View, CA, USA) with
488 nm Argon Laser excitation wavelength and threeies (polyvalent or monoclonal preparations).
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Table 2. Allele assignment of the 18 lymphoblastoid cell lines (LCL) analysis was performed with variables having a signifi-
used in the test panel
cant impact on graft survival using the Cox-Regression
Workshop HLA-DR model. For all covariates the proportional hazard was
number Name (previous equivalents)
assumed visually. During Cox analysis (forward condi-
9004 JESTHOM 1 tional), the probability for stepwise entry of covariates9009 KAS 011 16 (2)
9013 SCHU 15 (2) was P 5 0.05 and for removal was P 5 0.1.
9021 RSH 18 (3)
9022 COX 17 (3)
9031 BOLETH 4
RESULTS9036 SP0010 11 (5)
9038 BM16 12 (5) Detection of humoral alloreactivity in vivo and9051 PITOUT 7
9060 CB6B 13 (6) in vitro
9061 31227ABO 14 (6)
Figure 1 shows the capillary deposition of complement9063 WT47 13 (6)
9068 BM9 8 fragment C4d in graft biopsies. There were three staining
9070 LUY 8 patterns: C4d1 indicates staining of all, C4d(1) staining9075 DKB 9
of few, and C4d2 absent staining of interstitial capillar-9078 PMG075 1
9089 BOB 11 (5) ies. Because the staining of only few capillaries was a
9092 BM92 4
transitional state from C4d1 to C4d2 and vice versa,
the C4d(1) cases were evaluated as C4d1. If a transplant
was repeatedly biopsied and one biopsy (the index
biopsy) showed capillary C4d, the transplant was evalu-filters for the emitted fluorescence at 530 6 30 nm, 585
ated as C4d1. If all biopsies from a given graft werenm 6 42 nm, and .650 nm. Nonreactivity in the two-
either positive or negative, the first biopsy was taken ascolor cytofluorimetric assay was defined by serum sam-
the index biopsy. All data presented here refer to indexples taken from normal volunteers. Any patient serum
biopsies. Thus, 46% of first grafts and 72% of regraftscausing an increase in fluorescence intensity of at least
showed capillary C4d.25% was classified as positive.
A comparison with histopathological results showedPanel-reactive antibodies were assessed by the standard
microcytotoxicity technique of Terasaki and McClel- that capillary C4d occurred predominantly in rejections
land [16] using at least 50 typed lymphocyte samples. with vascular involvement (Table 3). Capillary C4d also
A panel reactivity of more than 5% was classified as could be found in other histologic entities such as acute
positive. tubular necrosis and different forms of transplant glo-
merulonephritis.
Antibodies used in flow cytometric analysis and in In 48 recipients, circulating alloantibodies in corre-
immunoperoxidase staining sponding serum samples at the time of biopsy were mea-
The following mouse monoclonal antibodies were sured using a conventional microcytotoxicity test (panel
used as primary antibodies: antibody specific for human reactivity) and flow cytometry (LCL reactivity). Table 4
endothelial cells (Pal-E, IgG2a; Monosan, Uden, Nether- shows that 18 recipients had circulating antibodies reac-
lands), anti-human complement fragment C4d (clone tive against LCL of donor DR type, and 19 recipients
M4d2 [17]), and anti-C4d (IgG1; Quidel, San Diego, CA, showed a panel reactivity of greater than 5%. Capillary
USA). The following antisera were used as secondary C4d in biopsies was significantly associated with LCL
antibodies: peroxidase-conjugated F(ab9)2-fragments of reactivity only (P 5 0.008).
rabbit anti-mouse immunoglobulins, F(ab9)2-fragments
of FITC-conjugated rabbit anti-human complement frag- Association of capillary C4d in biopsies with other
ment C4c (all from Dako, Carpinteria, CA, USA), and determinants of transplantation
F(ab9)2-fragments of PE-conjugated donkey anti-human
The distribution of recipient and donor determinantsIgG (Dianova, Hamburg, Germany).
among C4d1 and C4d2 transplant biopsies is listed in
Statistical analysis Table 5. Overall, capillary deposition of C4d is signifi-
cantly associated with graft losses (P 5 0.001), retrans-Statistical analysis was performed using the SPSS Proc-
plants (P 5 0.001), and preformed panel-reactive anti-essor 7.5 for Windows 95. The death of a graft recipient
bodies (.5%, P 5 0.005). Substantially fewer patientswas documented as graft failure. Graft survival according
received antilymphocyte antibody treatment in the C4d2to dichotomized variables was estimated using the
group. Other factors were not significantly associated withmethod of Kaplan–Meier and for each set the P value
of the log-rank statistic was calculated. A multivariate capillary complement deposition (Tables 1 and 5).
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Table 3. Distribution of histologic diagnoses and capillary




Borderline changes 7 8
Acute rejections
Banff grade I, IIA 27 37
Banff grade IIB 12 5
Banff grade III 4 0
Chronic allograft nephropathy 14 8
Other allograft nephropathy
Acute tubular necrosis 11 8
Vascular hyalinosis 1 2
Interstitial neutrophilic nephritis 0 2
Recurrent/de novo glomerulonephritis 6 4
Combined pathologya 19 10
Histological diagnoses refer to the predominant lesion in a given biopsy. Signs
under capillary deposition of C4d denote: (1) positive staining; (2) absent
staining.
a In grafts without predominating lesion but showing any combination of rejec-
tion with other pathological findings
Table 4. Capillary deposition of C4d in graft biopsies and antibody




Reactivity against LCL positive 14 4
of donor DR-typea negative 11 19 0.008
Panel-reactivity (.5%) positive 12 7
negative 13 16 0.3
Capillary deposition of C4d is defined by: (1) positive staining; (2) absent
staining. P values are by the Fisher’s exact test.
a Flow cytometry
half-life (50% surviving) of grafts with capillary deposi-
tion of C4d was only four years, whereas in the C4d
negative group, this interval was extended to eight years
after transplantation. To analyze the differential effects
of capillary deposition of C4d in early (#6 months post-
transplant) versus late (.6 months post-transplant) bi-
opsies, the cumulative survival was estimated separately
for both groups. Grafts with capillary C4d in early biop-
sies had a markedly reduced survival (75% graft survival
at one month and 50% survival at 16 months after trans-
plantation) as compared with grafts without capillary
C4d (75% survival at 38 months, 50% graft survival notFig. 1. Staining patterns of complement fragment C4d in renal graft
biopsies. (A) C4d1: staining of all interstitial capillaries. (B) C4d(1): reached during the observation period; Fig. 3A). Grafts
staining of only few capillaries. (C) C4d2: absent deposition of capillary with late biopsies had a comparable survival rate within
C4d (magnification 3120).
four years post-transplantation irrespective of the pres-
ence or absence of capillary C4d. There was a tendency
toward a superior survival of grafts without capillary C4d
Impact of capillary deposition of C4d and other in the late post-transplantation period (Fig. 3B).
variables on graft survival Other well-known variables that could have an impact
on graft survival are listed in Table 5. For each factor,The cumulative survival of biopsied renal allografts
with and without capillary deposition of complement the cumulative survival was analyzed separately using
the method of Kaplan–Meier, and the P value of theC4d was analyzed using the method of Kaplan–Meier
(log-rank statistic, P 5 0.0001; Fig. 2). The estimated log-rank statistic was calculated (Table 6).
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Table 5. Capillary deposition of C4d in renal transplant biopsies
and distribution of associated transplant
determinants in all cases (N 5 218)




no 33 56 0.001
Number of transplantations
1 69 82
.1 48 (41%) 19 (18.8%) 0.001
Preformed panel-reactive 16.27% 8.13%




no 67 82 0.0002




female 50 33 NS
Mismatches (mean6SD)
HLA-A 0.97 (60.72) 0.88 (60.69) NS
HLA-B 0.87 (60.71) 0.93 (60.74) NS
HLA-DR 1.35 (60.71) 0.61 (60.64) NS
Capillary deposition of Cd4 is defined as: (1) positive staining; (2) absent
staining. Pearson’s chi square test was used to calculate the P values.
a PRA # 5% vs. . 5%
Fig. 3. Survival of renal grafts with index biopsy performed within six
months after transplantation (A; P , 0.0001) and beyond six months
after transplantation (B; 1 censored cases).
1.7-fold relative risk for a donor age above 45 years, and
a 1.7-fold relative risk for patients with preformed panel-
reactive antibodies (.5%). In the subgroup of biopsies
performed within six months after transplantation, onlyFig. 2. Capillary C4d in biopsies and cumulative survival of renal grafts
(1 censored cases; P , 0.0001). two independent variables remained during Cox regres-
sion analysis. In these cases, the deposition of C4d in
capillaries is accompanied by a 3.1-fold relative risk of
To evaluate the most important independent risk fac- subsequent graft loss, followed by any mismatch at the
tors for the survival of biopsied renal allografts, a multi- HLA-DR locus (relative risk, 1.8). When grafts were
variate analysis was performed. Variables having a sig- biopsied later than six months after transplantation, no
nificant impact on graft survival (log rank statistic, P 5 variable had a significant impact on graft outcome.
0.01) were analyzed using the Cox regression model (Ta-
ble 6). Thus, during Cox regression, including all cases,
DISCUSSIONthree independent variables remained. Capillary deposi-
The present study elucidates the role of the humoraltion of C4d in renal allografts is accompanied by a 2.1-
fold relative risk of subsequent graft loss, followed by a immune system on the survival of renal allografts. In a
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Table 6. Impact of selected variables on the survival of biopsied able in 46% of first grafts and 72% of regrafts that under-
renal allografts
went biopsy and was prevalent in rejections showing
Multivariate analysis vascular involvement. As is depicted in Table 3, capillary
Cox regression model
Univariate C4d is represented in various other histologic categories
analysis Relative as well. Whether capillary C4d in these cases is predictive
Variablec P ad P e risk 95% CI
of subsequent vascular rejection has to be addressed in
All cases (N 5 218)b a larger study with serial biopsies.
Capillary deposition of C4d 0.0001 0.0002 2.1 1.4–3.1
Altogether, humoral alloreactions have a strong im-Preformed panel-reactive
antibodies 0.0001 0.007 1.7 1.2–2.5 pact on the survival of biopsied renal allografts, resulting
Donor age 0.001 0.004 1.7 1.1–2.5 in a half-life (50% of grafts surviving) of four years of
First-/retransplants 0.002 —g — —
grafts with capillary deposition of C4d, contrasted by aMismatches HLA-DR 0.03
Cold ischemia time 0.04 half-life of eight years of grafts without C4d (Fig. 2). In
Mismatches HLA-A and -B 0.3 a multivariate analysis using the Cox regression model,
Acute tubular necrosis 0.6
capillary C4d turned out to be the strongest independentAcute rejections 0.8
predictor of subsequent graft loss, followed by the pres-Renal allografts with biopsy
ence of preformed panel-reactive antibodies (.5%) andwithin 6 months after
transplantation (N 5 141)h a donor age above 45 years. Other well-known determi-
Capillary deposition of C4d 0.0001 0.0001 3.1 1.8–5.3 nants of graft survival, such as the occurrence of acuteFirst-/retransplants 0.0006 — — —
rejections and/or acute tubular necrosis, had no influencePreformed panel-reactive
antibodies 0.0007 — — — in this study with biopsied transplants.
Mismatches HLA-DR 0.007 0.02 1.8 1.1–2.9 Inspection of the survival graphs (Fig. 2) suggested anDonor age 0.008 — — —
influence of humoral immunity during the early post-Cold ischemia time 0.03
Mismatches HLA-A and -B 0.3 transplantation period and also during a later phase
Acute rejections 0.4 when chronic rejection usually develops. However, sub-Acute tubular necrosis 0.6
division into early (within 6 months) and late (beyond
Statistical analysis: SPSS-Processor 7.5 for Windows95, included in the multi-
6 months) humoral alloreactions revealed striking differ-variate analysis were only variables with a significant impact on graft survival
(P # 0.01 during univariate analysis) ences (Fig. 3). Humoral alloreactivity operative early
b Due to missing values 17 cases were excluded
after transplantation had a much stronger impact thanc Dichotomized variables, see also Table 1
dP value of the log-rank statistic alloreactivity during later periods. Detection of capillary
e Significance, Cox regression model
deposition of C4d within six months after transplantationf CI confidence interval
g Variables excluded during multivariate analysis was associated with a drastically reduced graft survival.
h Due to missing values 5 cases were excluded
In a multivariate analysis, it was the strongest predictor
of subsequent graft loss (relative risk, 3.1), followed by
any mismatch at the HLA-DR locus (relative risk, 1.8).
Humoral alloreactivity in later periods added minimalretrospective approach, a subgroup of renal allografts
necessitating biopsies was analyzed. Humoral alloreac- risk. It can be deduced that the immunopathogenic
mechanisms leading to adverse graft outcomes are con-tions operating within the first six months after trans-
plantation apparently have a much stronger effect than fined to the early post-transplantation period. Capillary
deposition of C4d heralds early graft loss within the firstthose beyond this period. The comprehensive assessment
of humoral alloreactivity is accomplished by analyzing year but has also an impact beyond this period.
The immediate and the delayed effects of humoralthe residues of classical complement activation in graft
capillaries and by including HLA class II-reactive alloan- immune reactions soon after transplantation again em-
phasize the critical importance of the early postoperativetibodies in the analysis of serum reactivity. Capillary
deposition of C4d in graft biopsies represents an immu- period. Other examples of early events with long-term
consequences would be the occurrence of delayed graftnohistochemical marker of humoral alloreactivity during
the course of acute and chronic rejections. function [19, 20] or the degree of reperfusion injury [21].
Also, in these instances, the progressive deterioration ofIt has been observed previously that rejections in the
presence of circulating alloantibodies show a high inci- organ function follows an early inciting event.
Humoral reactions late after transplantation, althoughdence of severe vascular lesions, whereas severe tubulitis
predominates in the absence of antibodies [18]. Notably, clearly detectable in serum samples and in biopsies, obvi-
ously do not significantly reduce graft survival, as thein these studies, graft capillaries were devoid of immuno-
globulins and complement components by conventional survival rate of C4d1 grafts is only slightly worse than
that of C4d2 grafts. This finding is surprising and war-immunofluorescence staining despite the presence of cir-
culating, donor-specific anti-HLA class I antibodies. In rants further investigation. We have not yet determined
whether early and late humoral attacks differ in strengththe present study, capillary deposition of C4d was detect-
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2. Almond PS, Matas A, Gillingham K, et al: Risk factors foror in other immunobiological properties of the immune
chronic rejection in renal allograft recipients. Transplantationresponse. For instance, differential modes of allorecogni- 55:752–757, 1993
tion, for example, preferential reactivity against donor 3. Tullius SG, Nieminen M, Bechstein WO, et al: Contribution of
early acute rejection episodes to chronic rejection in a rat kidneyHLA class I or class II molecules, allorecognition via
retransplantation model. Kidney Int 53:465–472, 1998direct or indirect pathways [22] or development of TH1
4. Cosio FG, Pelletier RP, Falkenhain ME, et al: Impact of acute
versus TH2 responses [23] have to be considered. Indi- rejection and early allograft function on renal allograft survival.
Transplantation 63:1611–1615, 1997rect recognition can result in the generation of T-cell
5. Vereerstraeten P, Abramowicz D, de Pauw L, et al: Absencehelp (TH1) for cell-mediated cytotoxic reactions, but
of deleterious effect on long-term kidney graft survival of rejection
also in help (TH2) for alloantibody production by B cells episodes with complete functional recovery. Transplantation
[24]. Thus, it has to be taken into account that antibody 63:1739–1743, 1997
6. van Saase JL, van der Woude FJ, Thorogood J, et al: The relationproduction might be a marker for a primary T-cell re-
between acute vascular and interstitial renal allograft rejection andsponse. subsequent graft loss. Transplantation 59:1280–1285, 1995
It is also notable that the survival of C4d negative 7. Kissmeyer-Nielsen F, Olsen F, Peterson VP, et al: Hyperacute
rejection of kidney allografts associated with pre-existing humoralgrafts in the late post-transplantation period is consider-
antibodies against donor cells. Lancet 1:662–665, 1966ably worse than that of complement-free grafts in the
8. Feucht HE, Opelz G: The humoral immune response towardsearly period. Thus, grafts that necessitated biopsy late HLA class II determinants in renal transplantation. Kidney Int
after transplantation seem to be uniformly affected by 50:1464–1475, 1996
9. McDouall RM, Batten P, McCormack A, et al: MHC class IInonhumoral forces that constrain their survival. These
expression on human heart microvascular endothelial cells: Exqui-forces may represent alloantigen-independent factors such
site sensitivity to interferon-gamma and natural killer cells. Trans-
as arterial hypertension, drug nephrotoxicity, chronic vi- plantation 64:1175–1180, 1997
10. Lederer SR, Schneeberger H, Albert E, et al: Early renal graftral infection, hyperlipidemia, or delivery of insufficient
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oblastoid cell lines. Transplantation 61:313–319, 1996ity that C4d negative grafts in the late period nevertheless 11. Feucht HE, Schneeberger H, Hillebrand G, et al: Capillary
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